Omega Therapeutics Lands $85M in Financing Back to HomeCAMBRIDGE, MA, Omega Therapeutics announced the completion of an $85 million financing.
Omega TherapeuticsÂ™, a company pioneering a new category of genomic medicine through epigenomic programming, today announced the completion of an $85 million financing.
Coordinated changes in epigenomic programming drive the cellular variation that controls human biology, in both healthy and diseased states.
"We are advancing the frontiers of medicine through epigenomic programming," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics.
About Omega TherapeuticsOmega Therapeutics is a genomic medicine company advancing novel engineered therapeutics, Omega's Epigenomic Controllers, enabling controllable epigenomic programming into clinical development for a broad range of indications.
Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.
The number of real estate tech deals worldwide has increased consistently each year, amounting to 454 deals as of 2018.
Search Startup Around
Boost Your Discovery with Us
Advertise with us to boost your article, content pience, product, event, conference discovery to our readers which includes founders, startup enablers, investors and every key stakeholders from global startup eco-system.